Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrolling By Invitation
18 years - 99 years
All
Phase
2
1 Location
Brief description of study
Please refer to Section 2 of the full protocol (Study Objectives). Please refer to Section 8.1 of the full protocol (Study Endpoints). Please refer to Section 8.1 of the full protocol (Study Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: lymphoma, non-hodgkin
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833308
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
